放疗失败后的激素使用：加拿大泌尿肿瘤专家的一项调查
Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.
作者信息
Loblaw D Andrew, Pickles Tom, Cheung Patrick C, Lukka Himu, Faria Sergio, Klotz Laurence
机构信息
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, ON;
出版信息
Can Urol Assoc J. 2009 Dec;3(6):460-4. doi: 10.5489/cuaj.1175.
INTRODUCTION
A survey of Canadian uro-oncology specialists was performed to assess practice patterns of patients with recurrent prostate cancer postradiotherapy and to assess the feasibility of conducting a trial in this setting.
METHODS
There were 14 survey questions and 1 demographic question. Responses were reported by frequency.
RESULTS
There were 96 respondents. Most respondents use both prostate-specific antigen doubling time (PSAdt) and PSA level when deciding to start androgen deprivation therapy (ADT) in asymptomatic patients. About half of respondents start ADT when PSA is greater than 10 ng/mL or when the PSAdt is less than 6 months. Eighty-six percent felt that the timing of ADT was an important research question. Over 1500 patients per year were estimated as being available for such a trial.
CONCLUSION
After radiotherapy failure, respondents initiated ADT about half of the time when PSA is less than 10 ng/mL and/or PSAdt is less than 6 months. A clinical trial examining the timing of ADT has strong support and appears to be feasible.
引言
对加拿大泌尿肿瘤专家进行了一项调查，以评估放疗后复发性前列腺癌患者的治疗模式，并评估在这种情况下开展试验的可行性。
方法
有14个调查问题和1个人口统计学问题。结果按频率报告。
结果
有96名受访者。大多数受访者在决定对无症状患者开始雄激素剥夺治疗（ADT）时，会同时使用前列腺特异性抗原倍增时间（PSAdt）和PSA水平。约一半的受访者在PSA大于10 ng/mL或PSAdt小于6个月时开始ADT。86%的人认为ADT的时机是一个重要的研究问题。估计每年有超过1500名患者可用于此类试验。
结论
放疗失败后，当PSA小于10 ng/mL和/或PSAdt小于6个月时，约一半的受访者会开始ADT。一项研究ADT时机的临床试验得到了有力支持，且似乎可行。
Zotero 插件